Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra

University of Indonesia (UI)

Status and phase

Completed

Phase 4

Conditions

Malaria

Treatments

Drug: Dihydroartemisinin-piperaquine with primaquine

Study type

Interventional

Funder types

Other

Identifiers

NCT01389557

45114-2

45114 (Other Grant/Funding Number)

Details and patient eligibility

About

Artemisinin-based combination therapy (ACT) has been known to be controversial for stopping malaria transmission. The addition of primaquine (PQ) - the only drug commercially available that kills mature transmission stage - to such treatments might be necessary to eliminate this stage. A study is conducted to evaluate the efficacy of dihydroartemisinin-piperaquine (DHP) regimens with PQ on malaria transmission on a community wide level in Lempasing, Lampung, Sumatra.

Full description

A mass screening baseline survey enabled the description of malaria prevalence (P. falciparum and P. vivax). Malaria infected asymptomatic (from the mass screening) and symptomatic (malaria infected people attending the health center) people were enrolled in the study. Enrolled malaria infected subjects were treated with DHP and PQ according to the treatment regimen. The community was mass screened for malaria infections every 3 months and an incidence cohort screened every month for infections. The 3 aims were to look at malaria antibodies, haemoglobin levels and the incidence of malaria before and after the drug intervention.

Enrollment

77 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

All individuals residing Lempasing village, kecamatan Hanura, Lampung province during study period

Exclusion criteria

Individuals with severe or chronic disease (liver, kidney), infant and pregnant or breastfeeding woman
Individuals that refuse to sign informed consent are excluded.
normal glucose-6-phosphate dehydrogenase enzyme level based on qualitative test (Trinity Biotech® no 203, USA)
willingness to sign the informed-consent form